Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;74(12):1868-1871.
doi: 10.1002/art.42334. Epub 2022 Nov 9.

The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID-19 Era

Leonard H Calabrese  1 , Cassandra M Calabrese  1 , Elizabeth Kirchner  1 , Kevin Winthrop  2
Affiliations

The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID-19 Era

Leonard H Calabrese et al. Arthritis Rheumatol. 2022 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Considerations for the role of rheumatology practitioners in COVID‐19 outpatient management in immunocompromised patients, including prevention, treatment, and practitioner education.
See this image and copyright information in PMC

References

    1. Singson JR, Kirley PD, Pham H, et al. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID‐19—COVID‐NET, 10 States, March 2020‐February 2022. MMWR Morb Mortal Wkly Rep 2022;71:878–84. - PMC - PubMed
    1. Calabrese CM, Kirchner E, Husni EM, et al. Breakthrough SARS‐CoV‐2 infections in immune mediated disease patients undergoing B cell depleting therapy: a retrospective cohort analysis. Arthritis Rheumatol 2022;74:1906–15. - PMC - PubMed
    1. Centers for Disease Control and Prevention . COVID‐19 vaccines for people who are moderately or severely immunocompromised, 2022. URL: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immun....
    1. Sparks JA, Wallace ZS, Seet AM, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID‐19 severity in rheumatoid arthritis: Results from the COVID‐19 Global Rheumatology Alliance physician registry. Ann Rheum Dis 2021;80:1137–46. - PMC - PubMed
    1. Conway R, Grimshaw AA, Konig MF, et al. SARS‐CoV‐2 infection and COVID‐19 outcomes in rheumatic disease: a systematic literature review and meta‐analysis. Arthritis Rheumatol 2021;74:766–75. - PMC - PubMed